APP Pharmaceuticals Acquires Three Products From Nexus. Benztropine Mesylate, Levetiracetam and Tranexamic Acid Injectables are Newest Additions to Critical Care Portfolio

SCHAUMBURG, Ill. (BUSINESS WIRE)—May 23, 2012—APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it has acquired three products from Nexus Pharmaceuticals, Inc. Under terms of the agreement APP takes complete ownership of the products and becomes the Abbreviated New Drug Application (ANDA) holder for Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection.

"The addition of these products broadens an already extensive portfolio of injectable APP critical care products," said John Ducker, president and chief executive officer of APP Pharmaceuticals. "As leaders in the reliable supply of sterile generic injectable drugs, APP will continue to identify, develop and market products to meet customer needs."

Benztropine Mesylate Injection, USP (1mg/mL, 2 mL) is therapeutically equivalent to the reference-listed drug Cogentin®. Levetiracetam Injection (100 mg/ml, 5 mL) is therapeutically equivalent to the reference-listed drug Keppra®. Tranexamic Acid Injection (100 mg/mL, 10 mL) is therapeutically equivalent to the reference-listed drug Cyklokapron®. According to IMS Health, in 2011 these three products combined represented a total market value of more than $90 million in the United States.

About APP Pharmaceuticals, Inc.

APP Pharmaceuticals is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. APP Pharmaceuticals is a Fresenius Kabi Company. For more information, please visit the company's Web site at www.APPpharma.com.

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy "caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2011, Fresenius Kabi achieved sales of EUR 3,964 million and an operating profit of EUR 803 million. For more information visit the company's Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary of Fresenius SE & Co. KGaA.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission. The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company's expectations.

Cogentin® is a registered trademark of Akorn.
Keppra® is a registered trademark of UCB Pharma, S.A..
Cyklokapron® is a registered trademark of Pfizer.
2011 Dataview© IMS HEALTH

APP Contact
Matt Kuhn
Senior Director, Communications & Government Affairs
Fresenius Kabi USA
847-969-8026
matt.kuhn@fresenius-kabi.com